Intra-Cellular Therapies, Inc. reiterated earnings guidance for the full year 2024. Full year 2024, the company reiterated CAPLYTA net product sales guidance of $645 to $675 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.81 USD | -0.10% | +1.91% | -5.32% |
May. 16 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.32% | 7.17B | |
-0.28% | 90.59B | |
0.00% | 38.99B | |
-8.52% | 34.09B | |
+64.13% | 26.38B | |
-17.37% | 15.02B | |
-5.99% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024